Literature DB >> 27173461

Association between circulating irisin and insulin resistance in non-diabetic adults: A meta-analysis.

Shanhu Qiu1, Xue Cai1, Han Yin2, Martina Zügel3, Zilin Sun4, Jürgen Michael Steinacker3, Uwe Schumann3.   

Abstract

INTRODUCTION: Exogenous administration of recombinant irisin improves glucose metabolism. However, the association of endogenous circulating (plasma/serum) irisin with insulin resistance remains poorly delineated. This study was aimed to examine this association by meta-analyzing the current evidence without study design restriction in non-diabetic adults. MATERIALS/
METHODS: Peer-reviewed studies written in English from 3 databases were searched to December 2015. Studies that reported the association between circulating irisin and insulin resistance (or its reverse, insulin sensitivity) in non-diabetic non-pregnant adults (mean ages ≥18years) were included. The pooled correlation coefficient (r) and 95% confidence intervals (CIs) were calculated using a random-effects model. Subgroup analyses and meta-regression were performed to explore potential sources of heterogeneity.
RESULTS: Of the 195 identified publications, 17 studies from 15 articles enrolling 1912 participants reported the association between circulating irisin and insulin resistance. The pooled effect size was 0.15 (95% CI: 0.07 to 0.22) with a substantial heterogeneity (I(2)=55.5%). This association seemed to be modified by glycemic status (fasting blood glucose ≥6.1mmol/L versus <6.1mmol/L) and racial-ethnic difference (Asians versus Europeans versus Americans), but not by sex difference, sampling time-point, blood sample type, ELISA kits used, baseline age, or body mass index. Circulating irisin was inversely associated with insulin sensitivity (6 studies; r=-0.17, 95% CI: -0.25 to -0.09).
CONCLUSIONS: Circulating irisin is directly and positively associated with insulin resistance in non-diabetic adults. However, this association is rather small and requires further clarification, in particular by well-designed large epidemiological studies with overall, race-, and sex-specific analyses.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Insulin resistance; Irisin; Meta-analysis

Mesh:

Substances:

Year:  2016        PMID: 27173461     DOI: 10.1016/j.metabol.2016.02.006

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  37 in total

Review 1.  Irisin in metabolic diseases.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Zoe A Efstathiadou; Polyzois Makras; Nikolaos Perakakis; Jannis Kountouras; Christos S Mantzoros
Journal:  Endocrine       Date:  2017-11-23       Impact factor: 3.633

Review 2.  Physiology and role of irisin in glucose homeostasis.

Authors:  Nikolaos Perakakis; Georgios A Triantafyllou; José Manuel Fernández-Real; Joo Young Huh; Kyung Hee Park; Jochen Seufert; Christos S Mantzoros
Journal:  Nat Rev Endocrinol       Date:  2017-02-17       Impact factor: 43.330

Review 3.  Measuring myokines with cardiovascular functions: pre-analytical variables affecting the analytical output.

Authors:  Giovanni Lombardi; Veronica Sansoni; Giuseppe Banfi
Journal:  Ann Transl Med       Date:  2017-08

Review 4.  The role of Irisin in multiorgan protection.

Authors:  Jun Ma; Ken Chen
Journal:  Mol Biol Rep       Date:  2021-01-03       Impact factor: 2.316

5.  Irisin and Visfatin Predicts Severity of Diabetic Nephropathy.

Authors:  Ramalingam Mageswari; M G Sridhar; H Nandeesha; Sreejith Parameshwaran; K V Vinod
Journal:  Indian J Clin Biochem       Date:  2018-03-21

6.  Irisin counteracts high glucose and fatty acid-induced cytotoxicity by preserving the AMPK-insulin receptor signaling axis in C2C12 myoblasts.

Authors:  Naohiro Yano; Ling Zhang; Dennis Wei; Patrycja M Dubielecka; Lei Wei; Shougang Zhuang; Ping Zhu; Gangjian Qin; Paul Y Liu; Y Eugene Chin; Ting C Zhao
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-03-17       Impact factor: 4.310

7.  Hyperirisinemia is independently associated with subclinical hypothyroidism: correlations with cardiometabolic biomarkers and risk factors.

Authors:  Theodora Stratigou; Maria Dalamaga; Georgios Antonakos; Ioanna Marinou; Evaggelos Vogiatzakis; Gerasimos Socrates Christodoulatos; Irene Karampela; Athanasios G Papavassiliou
Journal:  Endocrine       Date:  2018-02-17       Impact factor: 3.633

8.  Irisin as a Novel Marker for Insulin Resistance in Iraqi Women with Polycystic Ovary Syndrome Before and After Metformin Therapy.

Authors:  Fatin Shallal Farhan; Shatha Sami Hussien
Journal:  J Obstet Gynaecol India       Date:  2018-09-15

9.  Cardiometabolic health, visceral fat and circulating irisin levels: results from a real-world weight loss study.

Authors:  T Miazgowski; A Kaczmarkiewicz; B Miazgowski; J Kopeć
Journal:  J Endocrinol Invest       Date:  2020-09-06       Impact factor: 4.256

Review 10.  Progress and Challenges in the Biology of FNDC5 and Irisin.

Authors:  Steffen Maak; Frode Norheim; Christian A Drevon; Harold P Erickson
Journal:  Endocr Rev       Date:  2021-07-16       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.